Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Initiated the Industry’s First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A Readiness Activities …